Schott Pharma AG KGaA (FRA:1SX) OCF Margin %: 37.00% (As of Mar. 2026) — 82% Above Median


FRA:1SX Schott Pharma AG & CO KGaA FRA:1SX
67 GF Score
Price €4.04
GF Value €6.49
! 2 Warning Signs
View Full Analysis

What is Schott Pharma AG KGaA OCF Margin %?

Schott Pharma AG KGaA FRA:1SX -0.98% 67 OCF Margin % is 37.00% as of Mar. 2026, which is 82% above its 10-year median of 20.30. GuruFocus rates FRA:1SX with a GF Score™ of 67/100 and a GF Value™ of €6.49. The stock has 2 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 79.88% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Schott Pharma AG KGaA's Cash Flow from Operations for the three months ended in Mar. 2026 was €91.7 Mil. Schott Pharma AG KGaA's Revenue for the three months ended in Mar. 2026 was €247.9 Mil. Therefore, Schott Pharma AG KGaA's OCF Margin % for the quarter that ended in Mar. 2026 was 37.00%.

As of today, Schott Pharma AG KGaA's current OCF Yield % is 7.74%.

The historical rank and industry rank for Schott Pharma AG KGaA's OCF Margin % or its related term are showing as below:

FRA:1SX' s OCF Margin % Range Over the Past 10 Years
Min: 17.87   Med: 20.3   Max: 23.48
Current: 20.41


During the past 6 years, the highest OCF Margin % of Schott Pharma AG KGaA was 23.48%. The lowest was 17.87%. And the median was 20.30%.

FRA:1SX's OCF Margin % is ranked better than
79.88% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: 5.82 vs FRA:1SX: 20.41


Schott Pharma AG KGaA OCF Margin % Related Terms


Schott Pharma AG KGaA OCF Margin % Historical Data

* Premium members only.

The historical data trend for Schott Pharma AG KGaA's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Schott Pharma AG KGaA OCF Margin % Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
OCF Margin %
Get a 7-Day Free Trial 20.38 22.18 20.21 23.48 18.24

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.88 21.45 21.14 1.42 37.00

FRA:1SX vs ISRG, BDX, MDLN: OCF Margin % Comparison

For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Schott Pharma AG KGaA OCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Schott Pharma AG KGaA's OCF Margin % falls into.


FRA:1SX
67GF Score
Schott Pharma AG & CO KGaA FRA:1SX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Schott Pharma AG KGaA OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Schott Pharma AG KGaA's OCF Margin for the fiscal year that ended in Sep. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=179.92/986.21
=18.24 %

Schott Pharma AG KGaA's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=91.721/247.88
=37.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 37.00% mean?
Schott Pharma AG KGaA (FRA:1SX) has a OCF Margin % of 37.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Schott Pharma AG KGaA and its competitors. This is 82% above median its historical median of 20.30. Over the past decade, Schott Pharma AG KGaA's OCF Margin % has ranged from 17.87 to 23.48. According to the industry distribution chart, Schott Pharma AG KGaA ranks #164 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 20.1%.
Is Schott Pharma AG KGaA's OCF Margin % too high?
Schott Pharma AG KGaA's current OCF Margin % of 37.00% is 82% above median its 10-year median of 20.30. Over the past 10 years, this metric has ranged from a low of 17.87 to a high of 23.48. The Medical Devices & Instruments industry median OCF Margin % is 5.82. Schott Pharma AG KGaA's value of 37.00% is 535.7% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #164 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's OCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #164 out of 815 companies for OCF Margin %. This places Schott Pharma AG KGaA in the top 20% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 5.82. Schott Pharma AG KGaA's value of 37.00% is 535.7% above this benchmark. Historically, Schott Pharma AG KGaA's own OCF Margin % has ranged from 17.87 to 23.48 over the past decade. While the company's 10-year median is 20.30 vs. the industry median of 5.82, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.82, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current OCF Margin % of 37.00% is 535.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current OCF Margin % is 37.00%, which is 82% above median its own 10-year median of 20.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (FRA:1SX) has a current OCF Margin % of 37.00%. The stock's GF Value™ is €6.49, compared to a current price of €4.04 — trading 37.8% below its estimated fair value. The current OCF Margin % is 37.00%, which is 82% above median its 10-year median of 20.30 and 535.7% above the Medical Devices & Instruments industry median of 5.82. Schott Pharma AG KGaA's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Schott Pharma AG KGaA (FRA:1SX), the current OCF Margin % is 37.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Schott Pharma AG KGaA (FRA:1SX) Overvalued in 2026?

Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued. The current stock price of €4.04 is trading 37.8% below its estimated GF Value™ of €6.49.

Key valuation signals for FRA:1SX:

  • OCF Margin %: 37.00% (82% above median its 10-year median of 20.30)
  • GF Value™: €6.49 vs. price of €4.04 (37.8% below fair value)
  • GF Score™: 67/100 with 2 warning signs
  • Industry Position: 535.7% above the Medical Devices & Instruments median (#164 of 815)

No single metric tells the full story. See the FRA:1SX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Schott Pharma AG KGaA Business Description

Address Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
67GF Score

Get the complete analysis for FRA:1SX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.04
Price
€6.49
GF Value